Details of the Drug Combinations

General Information of This Drug (ID: DM6Q7U4)

Drug Name
Lenalidomide   DM6Q7U4
Synonyms
Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
Indication
Disease Entry ICD 11 Status REF
Adult T-cell leukemia/lymphoma N.A. Approved [1]
Advanced cancer 2A00-2F9Z Approved [1]
Complex regional pain syndrome type 1 N.A. Approved [1]
Hepatosplenic T-cell lymphoma N.A. Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Leukemia N.A. Approved [1]
MALT lymphoma N.A. Approved [1]
Multiple myeloma 2A83 Approved [2]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Pain MG30-MG3Z Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Prolymphocytic leukaemia 2A82.1 Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma N.A. Approved [1]
Splenic marginal zone lymphoma N.A. Approved [1]
Testicular lymphoma N.A. Approved [1]
Urinary bladder neoplasm N.A. Approved [1]
Waldenstrom macroglobulinemia 2A85.4 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Colon cancer 2B90.Z Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

486 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Lenalidomide DCS0YIN ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [4]
Cabazitaxel + Lenalidomide DCSXHMV Cabazitaxel Adenocarcinoma (Cell Line: HT29) [4]
Cabazitaxel + Lenalidomide DCZFRF4 Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [4]
Cabazitaxel + Lenalidomide DCI6H51 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Cabazitaxel + Lenalidomide DCA18F5 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Cabazitaxel + Lenalidomide DCM369C Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Cabazitaxel + Lenalidomide DCEJIQP Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [4]
Cabazitaxel + Lenalidomide DC1Z5DE Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [4]
Cabazitaxel + Lenalidomide DCPZ4RQ Cabazitaxel Invasive ductal carcinoma (Cell Line: BT-549) [5]
Crizotinib + Lenalidomide DCN52D8 Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Crizotinib + Lenalidomide DCLN28A Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Crizotinib + Lenalidomide DC8RZBD Crizotinib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Epirubicin + Lenalidomide DCGSB47 Epirubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Epirubicin + Lenalidomide DCQVOJZ Epirubicin Carcinoma (Cell Line: RXF 393) [5]
Epirubicin + Lenalidomide DCO4U18 Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Epirubicin + Lenalidomide DCHOGJ6 Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Indazole derivative 5 + Lenalidomide DCC0P93 Indazole derivative 5 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Indazole derivative 5 + Lenalidomide DCG1728 Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [6]
Indazole derivative 5 + Lenalidomide DC7OEZS Indazole derivative 5 Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Mechlorethamine DCG6O7K Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Mechlorethamine DC948XM Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Picoplatin DCC1CEA Picoplatin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Lenalidomide + Picoplatin DC9I9IH Picoplatin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Lenalidomide + Fulvestrant DCHDW0N Fulvestrant Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Fulvestrant DC3AK70 Fulvestrant Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Gefitinib DCKLS66 Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + Gefitinib DC9WX1K Gefitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Gefitinib DCZXT06 Gefitinib Glioma (Cell Line: SF-539) [4]
Lenalidomide + Hepzato DCPKA09 Hepzato Glioma (Cell Line: SF-268) [4]
Lenalidomide + Dactinomycin DCMXKFW Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Lenalidomide + Dactinomycin DCFJCJX Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + Dactinomycin DCSTFDF Dactinomycin Astrocytoma (Cell Line: SNB-19) [4]
Lenalidomide + Dactinomycin DCFV25L Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Lenalidomide + Dactinomycin DCUBUPC Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Dactinomycin DC513G2 Dactinomycin Glioma (Cell Line: SF-268) [4]
Lenalidomide + Dactinomycin DC58GSK Dactinomycin Glioma (Cell Line: SF-295) [4]
Lenalidomide + Dactinomycin DCJAWCX Dactinomycin Glioma (Cell Line: SF-539) [4]
Lenalidomide + Dactinomycin DCNE986 Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Lenalidomide + Dactinomycin DCL00OL Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Dactinomycin DCHJ6TG Dactinomycin Renal cell carcinoma (Cell Line: UO-31) [4]
Lenalidomide + Dactinomycin DCY13D9 Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [4]
Lenalidomide + Lapatinib DCFGF3Z Lapatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Lapatinib DCDWRWP Lapatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Lenalidomide + PMID28460551-Compound-2 DCMS4TH PMID28460551-Compound-2 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + Crizotinib DC99Q2F Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Cyclophosphamide DCYJA5F Cyclophosphamide Glioma (Cell Line: SF-268) [4]
Lenalidomide + Cyclophosphamide DCV19Y5 Cyclophosphamide Glioma (Cell Line: SF-539) [4]
Lenalidomide + Panobinostat DCBGQDU Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Lenalidomide + Methotrexate DCHUQJD Methotrexate Chronic myelogenous leukemia (Cell Line: K-562) [4]
Lenalidomide + Methotrexate DC5IXDC Methotrexate Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Lenalidomide + Methotrexate DCZ64PP Methotrexate Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Lenalidomide + Methotrexate DCW630K Methotrexate Renal cell carcinoma (Cell Line: UO-31) [4]
Lenalidomide + Isoniazid DCOO0YZ Isoniazid Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Arsenic trioxide DCJBOQN Arsenic trioxide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Lenalidomide + Arsenic trioxide DCFS8BW Arsenic trioxide Astrocytoma (Cell Line: SNB-19) [4]
Lenalidomide + Arsenic trioxide DCKQNUQ Arsenic trioxide Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Plicamycin DCSRLWD Plicamycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Plicamycin DC4GZ3L Plicamycin Glioma (Cell Line: SF-295) [4]
Lenalidomide + Plicamycin DCE2F51 Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Thioguanine DC9TF8U Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + Amonafide DCB9JJ9 Amonafide Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Pralatrexate DC8VRJJ Pralatrexate Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Pralatrexate DC6E0BT Pralatrexate Renal cell carcinoma (Cell Line: UO-31) [4]
Lenalidomide + Terameprocol DC5EXVJ Terameprocol Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Lenalidomide + Terameprocol DCL8AGF Terameprocol Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + SCH 727965 DCUM7RX SCH 727965 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + SCH 727965 DCJUHQ2 SCH 727965 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Ifosfamide DCG0K2E Ifosfamide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Ifosfamide DC11VQS Ifosfamide Renal cell carcinoma (Cell Line: UO-31) [4]
Lenalidomide + Dexrazoxane DC60882 Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Dexrazoxane DCEU6XM Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + Dexrazoxane DCC18RB Dexrazoxane Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Dexrazoxane DCJM84P Dexrazoxane Clear cell renal cell carcinoma (Cell Line: A498) [4]
Lenalidomide + Dexrazoxane DCF6XTE Dexrazoxane Glioma (Cell Line: SF-539) [4]
Lenalidomide + Dexrazoxane DCTA3J6 Dexrazoxane Glioma (Cell Line: SF-268) [4]
Lenalidomide + Dexrazoxane DCY8LXN Dexrazoxane Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Lenalidomide + Raloxifene DCPS20I Raloxifene Astrocytoma (Cell Line: U251) [4]
Lenalidomide + Raloxifene DCAHB7Q Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Raloxifene DCEE145 Raloxifene Glioma (Cell Line: SF-268) [4]
Lenalidomide + Bendamustine hydrochloride DCFIXWL Bendamustine hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Bendamustine hydrochloride DCUBGTZ Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Lenalidomide + Bendamustine hydrochloride DCEWDML Bendamustine hydrochloride Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Mitomycin DCXD5SN Mitomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Lenalidomide + Mitomycin DCTY04F Mitomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + SY-1425 DC8RGAV SY-1425 Glioma (Cell Line: SF-268) [4]
Lenalidomide + SY-1425 DCZQ3QT SY-1425 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Uracil mustard DCSWOZQ Uracil mustard Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Lenalidomide + Uracil mustard DCXMVRX Uracil mustard Glioma (Cell Line: SF-295) [4]
Lenalidomide + BIO-300 DCTFX1X BIO-300 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + Altretamine DCYLTM9 Altretamine Astrocytoma (Cell Line: SNB-19) [4]
Lenalidomide + Altretamine DCWMR29 Altretamine Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Altretamine DCL1ZGK Altretamine Glioblastoma (Cell Line: SNB-75) [4]
Lenalidomide + Altretamine DC79AWO Altretamine Glioma (Cell Line: SF-268) [4]
Lenalidomide + Idarubicin DCJSPQ4 Idarubicin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Idarubicin DCR7K00 Idarubicin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + Idarubicin DCOHY99 Idarubicin Astrocytoma (Cell Line: SNB-19) [4]
Lenalidomide + Idarubicin DCVQZDY Idarubicin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Lenalidomide + Idarubicin DCSJTMO Idarubicin Glioblastoma? (Cell Line: T98G) [4]
Lenalidomide + ONC201 DCZ00QE ONC201 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Lenalidomide + Imatinib DCSEEUA Imatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lenalidomide + Imatinib DCQF6V7 Imatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Imatinib DCV8IR7 Imatinib Renal cell carcinoma (Cell Line: UO-31) [4]
Lenalidomide + LEE011 DCIJ6MU LEE011 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Lenalidomide + Bleomycin DC3RI4F Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + Bleomycin DCGPT8C Bleomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Bleomycin DCOQUAM Bleomycin Glioma (Cell Line: SF-539) [4]
Lenalidomide + Anastrozole DC0UG5H Anastrozole Clear cell renal cell carcinoma (Cell Line: A498) [4]
Lenalidomide + Anastrozole DCGLJE1 Anastrozole Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Anastrozole DC6VD9E Anastrozole Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Lenalidomide + Anastrozole DCXWW4B Anastrozole Renal cell carcinoma (Cell Line: UO-31) [4]
Lenalidomide + Mebendazole DC2S182 Mebendazole Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Lenalidomide + Topotecan DCFOJYB Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Topotecan DCTXHJK Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Lenalidomide + Topotecan DC7VR2D Topotecan Glioma (Cell Line: SF-268) [4]
Lenalidomide + Cisplatin DCLF64X Cisplatin Glioma (Cell Line: SF-268) [4]
Lenalidomide + Cisplatin DCKA8CR Cisplatin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Chlorambucil DCK13H1 Chlorambucil Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Azacitidine DC890UZ Azacitidine Glioblastoma (Cell Line: SNB-75) [4]
Lenalidomide + Azacitidine DCENO3T Azacitidine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Pomalidomide DCV867J Pomalidomide Renal cell carcinoma (Cell Line: SN12C) [4]
Lenalidomide + Vinflunine DC0SEMO Vinflunine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + THZ1 DCQZBVG THZ1 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Lenalidomide + Mepacrine DC7F9HT Mepacrine Renal cell carcinoma (Cell Line: UO-31) [4]
Lenalidomide + Doxorubicin DCJALP5 Doxorubicin Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Lenalidomide + PMID28870136-Compound-43 DCHA4ZH PMID28870136-Compound-43 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Lenalidomide + PMID28870136-Compound-43 DC34IAH PMID28870136-Compound-43 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lenalidomide + PMID28870136-Compound-43 DCPCJCT PMID28870136-Compound-43 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Lenalidomide + PMID28870136-Compound-43 DCAZXDU PMID28870136-Compound-43 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Busulfan DCAM0AS Busulfan Chronic myelogenous leukemia (Cell Line: K-562) [4]
Lenalidomide + Busulfan DC93A1I Busulfan Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lenalidomide + Ibrutinib DC631RU Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [4]
Lenalidomide + Dasatinib DCIHZYK Dasatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lenalidomide + Picoplatin DCX61BE Picoplatin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Picoplatin DCATFTA Picoplatin Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Picoplatin DCCB4UD Picoplatin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Lenalidomide + Dactinomycin DCY9Q6V Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Dactinomycin DCRTBXU Dactinomycin Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Dactinomycin DCH88KA Dactinomycin Carcinoma (Cell Line: MCF7) [5]
Lenalidomide + Dactinomycin DCA37LB Dactinomycin Colon adenocarcinoma (Cell Line: COLO 205) [5]
Lenalidomide + Dactinomycin DCZ2VYN Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Dactinomycin DCM33FD Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Dactinomycin DCQ9P2O Dactinomycin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Lenalidomide + PMID28460551-Compound-2 DCCPYVP PMID28460551-Compound-2 Colon carcinoma (Cell Line: KM12) [5]
Lenalidomide + Crizotinib DC17OSV Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Cyclophosphamide DCM1CNO Cyclophosphamide Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Isoniazid DC24XPK Isoniazid Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Isoniazid DCDI09W Isoniazid Carcinoma (Cell Line: MCF7) [5]
Lenalidomide + Isoniazid DCXQDGW Isoniazid Colon carcinoma (Cell Line: KM12) [5]
Lenalidomide + Arsenic trioxide DCPO80W Arsenic trioxide Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Arsenic trioxide DCZIEXG Arsenic trioxide Carcinoma (Cell Line: MCF7) [5]
Lenalidomide + Plicamycin DCGJB2R Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Plicamycin DCOU517 Plicamycin Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Plicamycin DC99LBU Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Plicamycin DCPEW12 Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Nilotinib DCM2FO4 Nilotinib Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Nilotinib DCSSX18 Nilotinib Colon adenocarcinoma (Cell Line: COLO 205) [5]
Lenalidomide + Thioguanine DCEY8PY Thioguanine Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Triapine DC9HE87 Triapine Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Triapine DCVVVHD Triapine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Lenalidomide + Terameprocol DCRL0IJ Terameprocol Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Terameprocol DC2V8MY Terameprocol Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Terameprocol DCHVSKR Terameprocol Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + SCH 727965 DC4BQVM SCH 727965 Colon adenocarcinoma (Cell Line: COLO 205) [5]
Lenalidomide + Dexrazoxane DCEFOB4 Dexrazoxane Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Dexrazoxane DCQF1KP Dexrazoxane Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Dexrazoxane DCGOKI4 Dexrazoxane Colon adenocarcinoma (Cell Line: COLO 205) [5]
Lenalidomide + Dexrazoxane DCMFBU8 Dexrazoxane Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Bendamustine hydrochloride DC6HT0C Bendamustine hydrochloride Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Bendamustine hydrochloride DC0DN5V Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Mitomycin DC0LSLF Mitomycin Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Mitomycin DC3C7D9 Mitomycin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Mitomycin DCIRBI5 Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Uracil mustard DCWDXGL Uracil mustard Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Arfolitixorin DCN4HFP Arfolitixorin Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Altretamine DCFYGVN Altretamine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Lenalidomide + Idarubicin DCM5HWX Idarubicin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Idarubicin DCSTUS9 Idarubicin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Bleomycin DCVPC0X Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Bleomycin DCD7EFC Bleomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Anastrozole DC3NAN2 Anastrozole Colon adenocarcinoma (Cell Line: COLO 205) [5]
Lenalidomide + Anastrozole DCPVG7R Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Dacarbazine DCM8S9K Dacarbazine Invasive ductal carcinoma (Cell Line: T-47D) [5]
Lenalidomide + Topotecan DCN4KVC Topotecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Topotecan DCSHYS4 Topotecan Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Cisplatin DC46A7B Cisplatin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Chlorambucil DCIC8VD Chlorambucil Invasive ductal carcinoma (Cell Line: T-47D) [5]
Lenalidomide + ER819762 DCQBYG3 ER819762 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Lenalidomide + ER819762 DCKUTYG ER819762 Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + ER819762 DCVOYG0 ER819762 Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Romidepsin DC1A03H Romidepsin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Pomalidomide DC8525P Pomalidomide Colon carcinoma (Cell Line: KM12) [5]
Lenalidomide + Pomalidomide DCOV7X0 Pomalidomide Invasive ductal carcinoma (Cell Line: BT-549) [5]
Lenalidomide + Mercaptopurine DCPB867 Mercaptopurine Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Mepacrine DCC15YH Mepacrine Colon carcinoma (Cell Line: KM12) [5]
Lenalidomide + PMID28870136-Compound-43 DCWLE1S PMID28870136-Compound-43 Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + PMID28870136-Compound-43 DC3P9MK PMID28870136-Compound-43 Colon adenocarcinoma (Cell Line: COLO 205) [5]
Lenalidomide + PMID28870136-Compound-43 DCKYDBN PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Lenalidomide + PMID28870136-Compound-43 DCGV505 PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Lenalidomide + Busulfan DCJOFPZ Busulfan Carcinoma (Cell Line: MCF7) [5]
Lenalidomide + Dasatinib DC57Z1L Dasatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Lenalidomide + Mechlorethamine DCIV1GZ Mechlorethamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Lenalidomide + Mechlorethamine DC1MYHO Mechlorethamine Malignant melanoma (Cell Line: LOX IMVI) [6]
Lenalidomide + Pentostatin DC8WAKP Pentostatin Adenocarcinoma (Cell Line: SW-620) [6]
Lenalidomide + Pentostatin DC4YOHS Pentostatin Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Pentostatin DCTJEFW Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Pentostatin DC4GAVU Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Pentostatin DC9W6JK Pentostatin Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Picoplatin DCDIJSM Picoplatin Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Picoplatin DCXT0DU Picoplatin Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Picoplatin DCLT4VL Picoplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Picoplatin DCEQKBK Picoplatin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Lenalidomide + Picoplatin DCTMBN3 Picoplatin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Lenalidomide + Picoplatin DC2MICL Picoplatin Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Picoplatin DCLPCQR Picoplatin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Lenalidomide + Fulvestrant DCJK0B4 Fulvestrant Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + Fulvestrant DC08HY7 Fulvestrant Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Fulvestrant DCC0NYI Fulvestrant Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Gefitinib DCVOLWR Gefitinib Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Hepzato DCW2EQH Hepzato Adenocarcinoma (Cell Line: A549) [6]
Lenalidomide + Hepzato DCRN2XC Hepzato Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + Hepzato DCQMM0T Hepzato Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Hepzato DC7PCMQ Hepzato Adenocarcinoma (Cell Line: HCT116) [6]
Lenalidomide + Hepzato DCSH414 Hepzato Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Hepzato DCNCMBS Hepzato Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Ixabepilone DC5I7SL Ixabepilone Adenocarcinoma (Cell Line: HCT-15) [6]
Lenalidomide + Ixabepilone DCJHW0J Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Dactinomycin DCGKB9U Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [6]
Lenalidomide + Dactinomycin DCR0NQ4 Dactinomycin Adenocarcinoma (Cell Line: HCT116) [6]
Lenalidomide + Dactinomycin DCMVC5K Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Dactinomycin DCCEGAJ Dactinomycin Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Dactinomycin DCF4X1R Dactinomycin Adenocarcinoma (Cell Line: SW-620) [6]
Lenalidomide + Dactinomycin DCT2BZ9 Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Dactinomycin DC6MD81 Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Dactinomycin DCG0D2Q Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Lenalidomide + Dactinomycin DCWRWI7 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Lenalidomide + Dactinomycin DCYMGRX Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Lenalidomide + Dactinomycin DCFS87M Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Lenalidomide + Dactinomycin DCRHIKJ Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [6]
Lenalidomide + Dactinomycin DC7YF36 Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Lenalidomide + Dactinomycin DC1OZO5 Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Lenalidomide + Dactinomycin DCUIKS4 Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [6]
Lenalidomide + Dactinomycin DCRLEZS Dactinomycin Malignant melanoma (Cell Line: UACC62) [6]
Lenalidomide + Dactinomycin DCQ7ETJ Dactinomycin Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Dactinomycin DCAMGW7 Dactinomycin Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Dactinomycin DCNSALU Dactinomycin Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Dactinomycin DC2AWMC Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Dactinomycin DCMWQ10 Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Dactinomycin DCRKA3N Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Lenalidomide + Dactinomycin DCLFZUM Dactinomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Lenalidomide + Dactinomycin DCWYT2E Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + Lapatinib DCV9SF1 Lapatinib Adenocarcinoma (Cell Line: A549) [6]
Lenalidomide + Lapatinib DCS7LLI Lapatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lenalidomide + Lapatinib DCCWAIH Lapatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Lapatinib DCUBJF9 Lapatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Lenalidomide + PMID28460551-Compound-2 DCM89ZI PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Lenalidomide + PMID28460551-Compound-2 DC6ZZ76 PMID28460551-Compound-2 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Cyclophosphamide DCQAHLQ Cyclophosphamide Adenocarcinoma (Cell Line: OVCAR3) [6]
Lenalidomide + Cyclophosphamide DCDB4X1 Cyclophosphamide Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Cyclophosphamide DCPGZMR Cyclophosphamide Lung adenocarcinoma (Cell Line: EKVX) [6]
Lenalidomide + Cyclophosphamide DCBL3N6 Cyclophosphamide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Cyclophosphamide DCOMM3T Cyclophosphamide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Lenalidomide + LIAROZOLE DCKZHXU LIAROZOLE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + LIAROZOLE DCU4XEX LIAROZOLE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + LIAROZOLE DCMQ8YU LIAROZOLE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + Methotrexate DC2RRS2 Methotrexate Adenocarcinoma (Cell Line: A549) [6]
Lenalidomide + Methotrexate DCIEWHP Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Lenalidomide + Methotrexate DCNK0XN Methotrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Lenalidomide + Methotrexate DCDXUXT Methotrexate Prostate carcinoma (Cell Line: PC-3) [6]
Lenalidomide + Isoniazid DCSOCMZ Isoniazid Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Isoniazid DC3XU0H Isoniazid Amelanotic melanoma (Cell Line: M14) [6]
Lenalidomide + Isoniazid DCO7PX2 Isoniazid Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Isoniazid DC3KFLW Isoniazid Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Isoniazid DC8Z4VI Isoniazid Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + Arsenic trioxide DCS70VN Arsenic trioxide Adenocarcinoma (Cell Line: DU-145) [6]
Lenalidomide + Arsenic trioxide DCTSNP4 Arsenic trioxide Adenocarcinoma (Cell Line: HCT-15) [6]
Lenalidomide + Arsenic trioxide DCYH18O Arsenic trioxide Adenocarcinoma (Cell Line: HCT116) [6]
Lenalidomide + Arsenic trioxide DCBWSPB Arsenic trioxide Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Vemurafenib DC0SHW0 Vemurafenib Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + Vemurafenib DC41NZB Vemurafenib Prostate carcinoma (Cell Line: PC-3) [6]
Lenalidomide + Plicamycin DCDGNVH Plicamycin Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Plicamycin DCTNZPD Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Plicamycin DCSKR1I Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Plicamycin DCJVBK2 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Lenalidomide + Plicamycin DC4P8S4 Plicamycin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Lenalidomide + Plicamycin DC3HPS3 Plicamycin Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Plicamycin DCNQ56B Plicamycin Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Plicamycin DCTOJTU Plicamycin Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Plicamycin DCRDTDB Plicamycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Plicamycin DCKJFE4 Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + Nilotinib DCGJOU7 Nilotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lenalidomide + Nilotinib DCAWVV0 Nilotinib Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Triapine DCB5UGS Triapine Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Triapine DC4Q1IY Triapine Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Triapine DCON37T Triapine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Topetecan DC5JJ5R Topetecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Pralatrexate DCJFWN9 Pralatrexate Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + Pralatrexate DCGTDCK Pralatrexate Lung adenocarcinoma (Cell Line: HOP-62) [6]
Lenalidomide + Terameprocol DCMQG9R Terameprocol Adenocarcinoma (Cell Line: OVCAR3) [6]
Lenalidomide + Terameprocol DCCW4JM Terameprocol Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Terameprocol DC438Y6 Terameprocol Adenocarcinoma (Cell Line: HCT116) [6]
Lenalidomide + Terameprocol DCHRZGZ Terameprocol Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Terameprocol DCQZVT6 Terameprocol Adenocarcinoma (Cell Line: HCT-15) [6]
Lenalidomide + Terameprocol DCQULVA Terameprocol Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lenalidomide + Terameprocol DCGXGNC Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Terameprocol DCRQPXM Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Lenalidomide + Terameprocol DCTX2L6 Terameprocol Lung adenocarcinoma (Cell Line: EKVX) [6]
Lenalidomide + Terameprocol DCV5ADR Terameprocol Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Terameprocol DC9YTCS Terameprocol Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Terameprocol DCMKAIP Terameprocol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + SCH 727965 DCSJKKL SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + SCH 727965 DC22SL8 SCH 727965 Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lenalidomide + SCH 727965 DC5NWBP SCH 727965 Lung adenocarcinoma (Cell Line: MDA-MB-231) [6]
Lenalidomide + SCH 727965 DCE5F5D SCH 727965 Lung adenocarcinoma (Cell Line: HOP-62) [6]
Lenalidomide + SCH 727965 DC1Y8RB SCH 727965 Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Dexrazoxane DCIZQEU Dexrazoxane Adenocarcinoma (Cell Line: HCT116) [6]
Lenalidomide + Dexrazoxane DCFIBK1 Dexrazoxane Amelanotic melanoma (Cell Line: M14) [6]
Lenalidomide + Dexrazoxane DCNQM85 Dexrazoxane Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Lenalidomide + Dexrazoxane DCGSIYS Dexrazoxane Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Lenalidomide + Dexrazoxane DCM4TDK Dexrazoxane Malignant melanoma (Cell Line: LOX IMVI) [6]
Lenalidomide + Docetaxel DCU8GGJ Docetaxel Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Raloxifene DC5Y9SW Raloxifene Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Raloxifene DC9Q6MU Raloxifene Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lenalidomide + Raloxifene DCLOB17 Raloxifene Lung adenocarcinoma (Cell Line: HOP-62) [6]
Lenalidomide + Raloxifene DCT4W2O Raloxifene Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Bendamustine hydrochloride DC8MPZB Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [6]
Lenalidomide + Bendamustine hydrochloride DCYRR5F Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT116) [6]
Lenalidomide + Bendamustine hydrochloride DC89WLA Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT-15) [6]
Lenalidomide + Bendamustine hydrochloride DCWJ33M Bendamustine hydrochloride Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Bendamustine hydrochloride DC8R2Z8 Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Lenalidomide + Bendamustine hydrochloride DCSNZJ7 Bendamustine hydrochloride Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Bendamustine hydrochloride DC2ISIN Bendamustine hydrochloride Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Trifluridine DC3JIF7 Trifluridine Lung adenocarcinoma (Cell Line: HOP-62) [6]
Lenalidomide + Letrozole DCL5LBF Letrozole Adenocarcinoma (Cell Line: HCT116) [6]
Lenalidomide + Letrozole DCKGHX7 Letrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lenalidomide + Mitomycin DCBF2RY Mitomycin Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + Mitomycin DC2OZF3 Mitomycin Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Mitomycin DCO126F Mitomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Mitomycin DCXSB7H Mitomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + SY-1425 DCG2BUY SY-1425 Adenocarcinoma (Cell Line: OVCAR3) [6]
Lenalidomide + SY-1425 DCTM58K SY-1425 Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + SY-1425 DCDCI5I SY-1425 Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lenalidomide + SY-1425 DC8CHOL SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + SY-1425 DC36V8A SY-1425 Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Lenalidomide + SY-1425 DC49LTE SY-1425 Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Uracil mustard DCUSB4P Uracil mustard Malignant melanoma (Cell Line: LOX IMVI) [6]
Lenalidomide + Vincristine DCI74WO Vincristine Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Vincristine DCVQV96 Vincristine Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Lenalidomide + Arfolitixorin DC6XVG0 Arfolitixorin Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Arfolitixorin DCW548A Arfolitixorin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + BIO-300 DCP5N8V BIO-300 Prostate carcinoma (Cell Line: PC-3) [6]
Lenalidomide + Altretamine DCITGJX Altretamine Adenocarcinoma (Cell Line: DU-145) [6]
Lenalidomide + Altretamine DC8JNY2 Altretamine Adenocarcinoma (Cell Line: OVCAR3) [6]
Lenalidomide + Altretamine DCMZFBF Altretamine Adenocarcinoma (Cell Line: HCT-15) [6]
Lenalidomide + Altretamine DCJ18JR Altretamine Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Altretamine DCILU4U Altretamine Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Altretamine DCN6MTD Altretamine Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Idarubicin DCA1QN2 Idarubicin Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + Idarubicin DCSHSDR Idarubicin Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Idarubicin DCHOGVO Idarubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Idarubicin DCN93SY Idarubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Idarubicin DCBA7MB Idarubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + Imatinib DCIQUWO Imatinib Adenocarcinoma (Cell Line: A549) [6]
Lenalidomide + Imatinib DCTF6D3 Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Lenalidomide + Imatinib DCJO2W1 Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Lenalidomide + Imatinib DC6CGSV Imatinib Malignant melanoma (Cell Line: LOX IMVI) [6]
Lenalidomide + Imatinib DCY93FU Imatinib Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Bleomycin DCJFJT0 Bleomycin Adenocarcinoma (Cell Line: A549) [6]
Lenalidomide + Bleomycin DCFJ3CQ Bleomycin Adenocarcinoma (Cell Line: SW-620) [6]
Lenalidomide + Bleomycin DC994HE Bleomycin Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Bleomycin DCOU0NF Bleomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Bleomycin DCDA98Z Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Lenalidomide + Bleomycin DCCFM9N Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [6]
Lenalidomide + Bleomycin DCMD504 Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [6]
Lenalidomide + Bleomycin DCNVKN8 Bleomycin Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Bleomycin DC7RMS7 Bleomycin Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Bleomycin DCFWV0U Bleomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Bortezomib DC16SJH Bortezomib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Bortezomib DCAYP7O Bortezomib Malignant melanoma (Cell Line: UACC62) [6]
Lenalidomide + Bortezomib DCO8LF1 Bortezomib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + Anastrozole DCHASPZ Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Lenalidomide + Anastrozole DCRSPQM Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Lenalidomide + Anastrozole DC1VYMY Anastrozole Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Lenalidomide + Anastrozole DCS2PAQ Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [6]
Lenalidomide + Anastrozole DC5L3L7 Anastrozole Malignant melanoma (Cell Line: UACC62) [6]
Lenalidomide + Anastrozole DCGTLFM Anastrozole Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Anastrozole DCGJQN1 Anastrozole Non-small cell lung carcinoma (Cell Line: HOP-92) [6]
Lenalidomide + Anastrozole DC12DLB Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Lenalidomide + Anastrozole DCQWWC5 Anastrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + Anastrozole DCPW71W Anastrozole Prostate carcinoma (Cell Line: PC-3) [6]
Lenalidomide + Dacarbazine DC1QJGR Dacarbazine Amelanotic melanoma (Cell Line: M14) [6]
Lenalidomide + Valrubicin DCQXA45 Valrubicin Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Topotecan DCGECA3 Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Topotecan DCJ0OWX Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [6]
Lenalidomide + Topotecan DCDF6RC Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Lenalidomide + Topotecan DCNYHA2 Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Lenalidomide + Topotecan DCPYBLU Topotecan Lung adenocarcinoma (Cell Line: EKVX) [6]
Lenalidomide + Topotecan DCYI24Q Topotecan Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Topotecan DCPVLXW Topotecan Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Topotecan DCEDB27 Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Topotecan DCI83ZM Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Lenalidomide + Cisplatin DC1RFGE Cisplatin Adenocarcinoma (Cell Line: NCIH23) [6]
Lenalidomide + Cisplatin DCWDN1W Cisplatin Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Cisplatin DC2QVZR Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Cisplatin DCBGT6J Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Cisplatin DC5DDH0 Cisplatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [6]
Lenalidomide + Cisplatin DC5XPAL Cisplatin Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Cisplatin DCSMMVR Cisplatin Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Chlorambucil DCD4B2T Chlorambucil Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Chlorambucil DCEVC42 Chlorambucil Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Chlorambucil DCORA7P Chlorambucil Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Chlorambucil DCKFN3D Chlorambucil Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + Chlorambucil DC4SZTX Chlorambucil Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Sorafenib DC0MN0J Sorafenib Adenocarcinoma (Cell Line: DU-145) [6]
Lenalidomide + ER819762 DC1SWJL ER819762 Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + ER819762 DCFM2GD ER819762 Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + ER819762 DCS67DM ER819762 Malignant melanoma (Cell Line: UACC62) [6]
Lenalidomide + ER819762 DC02RCR ER819762 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Romidepsin DCUDZCU Romidepsin Adenocarcinoma (Cell Line: A549) [6]
Lenalidomide + Romidepsin DC0RN0G Romidepsin Lung adenocarcinoma (Cell Line: EKVX) [6]
Lenalidomide + Romidepsin DC8KPAK Romidepsin Lung adenocarcinoma (Cell Line: NCI-H522) [6]
Lenalidomide + Romidepsin DCEPNMK Romidepsin Malignant melanoma (Cell Line: LOX IMVI) [6]
Lenalidomide + Romidepsin DC1K15G Romidepsin Prostate carcinoma (Cell Line: PC-3) [6]
Lenalidomide + Azacitidine DCG9D4Q Azacitidine Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Azacitidine DCMVDSN Azacitidine Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Azacitidine DCN7M9I Azacitidine Large cell lung carcinoma (Cell Line: NCI-H460) [6]
Lenalidomide + Azacitidine DC8EK6C Azacitidine Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Pomalidomide DC32NWC Pomalidomide Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + Pomalidomide DC1EIU2 Pomalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Pomalidomide DCZ6DN7 Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [6]
Lenalidomide + Pomalidomide DCKCUDH Pomalidomide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + Mercaptopurine DCT0CIN Mercaptopurine Amelanotic melanoma (Cell Line: M14) [6]
Lenalidomide + Mercaptopurine DCBHU29 Mercaptopurine Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Mercaptopurine DCVQ6ID Mercaptopurine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Mercaptopurine DCSV8YA Mercaptopurine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Mepacrine DCXGNKR Mepacrine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Lenalidomide + Mepacrine DCPDJFR Mepacrine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + PMID28870136-Compound-43 DC1ANGU PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + PMID28870136-Compound-43 DCN9YKC PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT-15) [6]
Lenalidomide + PMID28870136-Compound-43 DCLOLMJ PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + PMID28870136-Compound-43 DC8LM5Q PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + PMID28870136-Compound-43 DC1C6D8 PMID28870136-Compound-43 Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + PMID28870136-Compound-43 DCK9X6X PMID28870136-Compound-43 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + PMID28870136-Compound-43 DCXKR1G PMID28870136-Compound-43 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [6]
Lenalidomide + FORMESTANE DC5J9F0 FORMESTANE Adenocarcinoma (Cell Line: HCT-15) [6]
Lenalidomide + FORMESTANE DCNRNL7 FORMESTANE Adenocarcinoma (Cell Line: HCC-2998) [6]
Lenalidomide + FORMESTANE DCIL3TN FORMESTANE Amelanotic melanoma (Cell Line: M14) [6]
Lenalidomide + FORMESTANE DCOPZXG FORMESTANE Melanoma (Cell Line: UACC-257) [6]
Lenalidomide + FORMESTANE DC5WHAG FORMESTANE Melanoma (Cell Line: MALME-3M) [6]
Lenalidomide + Aminolevulinic Acid Hydrochloride DCZF0L0 Aminolevulinic Acid Hydrochloride Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Lenalidomide + Aminolevulinic Acid Hydrochloride DC3YRWM Aminolevulinic Acid Hydrochloride Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Estramustine DCAF9V1 Estramustine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Digitoxin DC180UQ Digitoxin Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Busulfan DCBD02A Busulfan Adenocarcinoma (Cell Line: HCT-15) [6]
Lenalidomide + Busulfan DCZPD7U Busulfan Adenocarcinoma (Cell Line: HT29) [6]
Lenalidomide + Busulfan DCZGAV2 Busulfan Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Lenalidomide + Busulfan DC519YA Busulfan Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Lenalidomide + Busulfan DCDTC43 Busulfan Lung adenocarcinoma (Cell Line: EKVX) [6]
Lenalidomide + Busulfan DCK8KQF Busulfan Melanoma (Cell Line: SK-MEL-2) [6]
Lenalidomide + Busulfan DC6KEWD Busulfan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [6]
Lenalidomide + Busulfan DCMTAJ9 Busulfan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [6]
Lenalidomide + Busulfan DCNYXV0 Busulfan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [6]
Lenalidomide + Dasatinib DC20WT7 Dasatinib Adenocarcinoma (Cell Line: HCC-2998) [6]
MK-1775 + Lenalidomide DCQ1J4M MK-1775 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
PD-0325901 + Lenalidomide DC5C5RU PD-0325901 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Raloxifene + Lenalidomide DCMGRIM Raloxifene Adenocarcinoma (Cell Line: HCT116) [6]
Raloxifene + Lenalidomide DCOXF31 Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Raloxifene + Lenalidomide DCNW8WZ Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [6]
Raloxifene + Lenalidomide DCMJ3QO Raloxifene Prostate carcinoma (Cell Line: PC-3) [6]
Ruxolitinib + Lenalidomide DC03VCP Ruxolitinib Glioma (Cell Line: SF-268) [4]
Ruxolitinib + Lenalidomide DCL00Y8 Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Ruxolitinib + Lenalidomide DCW24XA Ruxolitinib Melanoma (Cell Line: MALME-3M) [6]
Vandetanib + Lenalidomide DCTY02U Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [6]
Vandetanib + Lenalidomide DCCHCUH Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Vandetanib + Lenalidomide DC9FINR Vandetanib Melanoma (Cell Line: SK-MEL-2) [6]
Vandetanib + Lenalidomide DCC509I Vandetanib Plasma cell myeloma (Cell Line: RPMI-8226) [6]
Vemurafenib + Lenalidomide DCJ5RLZ Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vemurafenib + Lenalidomide DCYOFFV Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vemurafenib + Lenalidomide DC0R7EY Vemurafenib Glioma (Cell Line: SF-268) [6]
Vemurafenib + Lenalidomide DCGD34V Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [6]
Vismodegib + Lenalidomide DCNQ396 Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Vismodegib + Lenalidomide DCG8TY6 Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [6]
Vismodegib + Lenalidomide DC8PSSX Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [6]
Vismodegib + Lenalidomide DCRPD78 Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-28) [6]
Vismodegib + Lenalidomide DCEW7PW Vismodegib Glioma (Cell Line: SF-268) [6]
Vismodegib + Lenalidomide DCP0TXY Vismodegib Melanoma (Cell Line: UACC-257) [6]
Vismodegib + Lenalidomide DC347TO Vismodegib Renal cell carcinoma (Cell Line: UO-31) [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 486 DrugCom(s)
55 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Carfilzomib + Lenalidomide DCTXXK8 Carfilzomib T-cell Lymphomas [7]
Cyclophosphamide + Lenalidomide DC7TDVR Cyclophosphamide Intraocular Melanoma [8]
Cyclophosphamide + Lenalidomide DCDYWB2 Cyclophosphamide Adenocarcinoma of the Prostate [9]
Cyclophosphamide + Lenalidomide DCUG6NF Cyclophosphamide Refractory Multiple Myeloma [10]
Dexamethasone + Lenalidomide DCD8TSN Dexamethasone Multiple Myeloma [11]
Dexamethasone + Lenalidomide DC0Y93T Dexamethasone Multiple Myeloma [12]
Dexamethasone + Lenalidomide DC18VJ2 Dexamethasone Refractory Multiple Myeloma [13]
Dexamethasone + Lenalidomide DC36V79 Dexamethasone Refractory Multiple Myeloma [14]
Dexamethasone + Lenalidomide DC5KSWK Dexamethasone Multiple Myeloma [15]
Dexamethasone + Lenalidomide DC7AK5T Dexamethasone Relapsed or Refractory Multiple Myeloma [16]
Dexamethasone + Lenalidomide DC9TIYU Dexamethasone Multiple Myeloma [17]
Dexamethasone + Lenalidomide DCO7BZC Dexamethasone Multiple Myeloma [18]
Idelalisib + Lenalidomide DCHP9FQ Idelalisib Recurrent Follicular Lymphoma [19]
Lenalidomide + Bendamustine hydrochloride DCRMGBA Bendamustine hydrochloride Lymphoma [20]
Lenalidomide + Bendamustine hydrochloride DC12TS8 Bendamustine hydrochloride Lymphoma [20]
Lenalidomide + Paclitaxel DC1KTN6 Paclitaxel Prostate Cancer [21]
Lenalidomide + CC-292 DC3HOS0 CC-292 Leukemia Lymphocytic Chronic B-Cell [22]
Lenalidomide + Vorinostat DC3WOYY Vorinostat Multiple Myeloma [23]
Lenalidomide + Cytarabine DC7X0IU Cytarabine Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities [24]
Lenalidomide + Everolimus DCAVIXU Everolimus Adult Nasal Type Extranodal NK/T-cell Lymphoma [25]
Lenalidomide + Irinotecan DCB1SLR Irinotecan Malignant Gliomas [26]
Lenalidomide + Azacitidine DCC5AOW Azacitidine Leukemia [27]
Lenalidomide + Gemcitabine DCCAFIK Gemcitabine Metastatic Pancreatic Cancer [28]
Lenalidomide + Fludarabine DCE8HNC Fludarabine Leukemia, Lymphocytic, Chronic, B-Cell [29]
Lenalidomide + Cyclosporin A DCESXKJ Cyclosporin A Myelodysplastic Syndrome [30]
Lenalidomide + Sunitinib DCI4BXC Sunitinib Renal Cell Carcinoma [31]
Lenalidomide + Vorinostat DCJ64A7 Vorinostat Adult Nasal Type Extranodal NK/T-cell Lymphoma [32]
Lenalidomide + Temsirolimus DCNK7LQ Temsirolimus Refractory Multiple Myeloma [33]
Lenalidomide + Bortezomib DCPAUOT Bortezomib Refractory Multiple Myeloma [34]
Lenalidomide + Azacitidine DCTAJLM Azacitidine Acute Myeloid Leukemia (AML) [35]
Lenalidomide + Romidepsin DCVYV4M Romidepsin Multiple Myeloma [36]
Lenalidomide + Valproic Acid DCYP3D5 Valproic Acid Solid Tumors [37]
Lenalidomide + Bortezomib DC6ELTN Bortezomib Myelodysplasia [38]
Lenalidomide + Etoposide DCFWOZ6 Etoposide Adult Acute Megakaryoblastic Leukemia (M7) [39]
Lenalidomide + Idarubicin DCR20ZK Idarubicin Myelodysplastic Syndrome [40]
Lenalidomide + Venetoclax DC4DEDR Venetoclax Recurrent B-Cell Non-Hodgkin Lymphoma [41]
Lenalidomide + Cytarabine DC4F3R9 Cytarabine Acute Myeloid Leukemia (AML) [42]
Lenalidomide + Umbralisib DC6KJNI Umbralisib Chronic Lymphocytic Leukemia [43]
Lenalidomide + Zanubrutinib DC7LCZN Zanubrutinib Relapsed/Refractory Diffuse Large B-Cell Lymphoma [44]
Lenalidomide + Venetoclax DCDZZ75 Venetoclax B-Cell Lymphoma, Unspecified [45]
Lenalidomide + Tazemetostat DCGJ3NV Tazemetostat Relapsed Hematologic Malignancy [46]
Lenalidomide + Umbralisib DCO2C97 Umbralisib Recurrent B-Cell Non-Hodgkin Lymphoma [47]
Selinexor + Lenalidomide DCWBO0J Selinexor Refractory Multiple Myeloma [48]
Dexamethasone + Lenalidomide DC4K2CO Dexamethasone Stage I Multiple Myeloma [49]
Dexamethasone + Lenalidomide DCA5S4Q Dexamethasone Refractory Plasma Cell Myeloma [50]
Dexamethasone + Lenalidomide DCB4LYI Dexamethasone Multiple Myeloma [51]
Dexamethasone + Lenalidomide DCCOQ02 Dexamethasone Multiple Myeloma [52]
Dexamethasone + Lenalidomide DCRFPHF Dexamethasone Multiple Myeloma [53]
Dexamethasone + Lenalidomide DCSQJB6 Dexamethasone Multiple Myeloma [54]
Lenalidomide + Romidepsin DC9Q0YM Romidepsin Adult Nasal Type Extranodal NK/T-cell Lymphoma [55]
Lenalidomide + Acalabrutinib DCS2BKF Acalabrutinib B-cell Lymphoma [56]
Selinexor + Lenalidomide DCO75M8 Selinexor Multiple Myeloma [57]
Dexamethasone + Lenalidomide DC8V2A3 Dexamethasone Multiple Myeloma [58]
Dexamethasone + Lenalidomide DCESWHA Dexamethasone Multiple Myeloma [59]
Lenalidomide + Colchicine DC02ZGK Colchicine Multiple Myeloma [60]
------------------------------------------------------------------------------------
⏷ Show the Full List of 55 DrugCom(s)

References

1 Lenalidomide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
3 Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial (GETAFE)
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
7 ClinicalTrials.gov (NCT02341014) Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
8 ClinicalTrials.gov (NCT00482911) Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
9 ClinicalTrials.gov (NCT01093183) Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
10 ClinicalTrials.gov (NCT00112827) Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
11 ClinicalTrials.gov (NCT00056160) CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
12 ClinicalTrials.gov (NCT01038388) A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
13 ClinicalTrials.gov (NCT01155583) Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
14 ClinicalTrials.gov (NCT03702725) Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
15 ClinicalTrials.gov (NCT00378105) Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
16 ClinicalTrials.gov (NCT00642954) Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
17 ClinicalTrials.gov (NCT01348919) Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
18 ClinicalTrials.gov (NCT01583283) Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
19 ClinicalTrials.gov (NCT01644799) Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
20 ClinicalTrials.gov (NCT01415752) Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
21 ClinicalTrials.gov (NCT00933426) Lenalidomide and Paclitaxel in Prostate Cancer
22 ClinicalTrials.gov (NCT01732861) Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
23 ClinicalTrials.gov (NCT00729118) Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
24 ClinicalTrials.gov (NCT01246622) Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
25 ClinicalTrials.gov (NCT01075321) Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
26 ClinicalTrials.gov (NCT00671801) Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
27 ClinicalTrials.gov (NCT00352001) Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
28 ClinicalTrials.gov (NCT00837031) Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
29 ClinicalTrials.gov (NCT00738829) Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
30 ClinicalTrials.gov (NCT00840827) Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes
31 ClinicalTrials.gov (NCT00975806) Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
32 ClinicalTrials.gov (NCT01116154) Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
33 ClinicalTrials.gov (NCT00398515) Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
34 ClinicalTrials.gov (NCT00153933) Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
35 ClinicalTrials.gov (NCT00890929) Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
36 ClinicalTrials.gov (NCT01755975) Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
37 ClinicalTrials.gov (NCT00495872) Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
38 ClinicalTrials.gov (NCT00580242) A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia
39 ClinicalTrials.gov (NCT01904643) Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
40 ClinicalTrials.gov (NCT00831766) Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
41 ClinicalTrials.gov (NCT04447716) An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
42 ClinicalTrials.gov (NCT02255162) Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
43 ClinicalTrials.gov (NCT03379051) Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
44 ClinicalTrials.gov (NCT04436107) Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
45 ClinicalTrials.gov (NCT02992522) Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
46 ClinicalTrials.gov (NCT05205252) A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
47 ClinicalTrials.gov (NCT04635683) Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
48 ClinicalTrials.gov (NCT04519476) Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
49 ClinicalTrials.gov (NCT01518465) Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
50 ClinicalTrials.gov (NCT02353468) Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
51 ClinicalTrials.gov (NCT00482261) A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
52 ClinicalTrials.gov (NCT00378209) Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
53 ClinicalTrials.gov (NCT03785184) A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
54 ClinicalTrials.gov (NCT03605056) Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
55 ClinicalTrials.gov (NCT02232516) Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
56 ClinicalTrials.gov (NCT05014100) Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
57 ClinicalTrials.gov (NCT05820763) Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
58 ClinicalTrials.gov (NCT03710603) Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
59 ClinicalTrials.gov (NCT01208662) Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
60 ClinicalTrials.gov (NCT05802992) The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients